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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.09.025Objective: Computed tomographic screening is detecting ever smaller peripheral
non–small cell lung cancers. These smaller cancers are amenable to sublobar
resection, but sublobar resection is not currently the treatment of choice. This study
compared sublobar resection with lobar resection for stage IA non–small cell lung
cancers to assess whether sublobar resection is appropriate treatment for certain
lesions. The use of adjuvant brachytherapy was also evaluated.
Methods: A retrospective multicenter study of 291 patients with T1 N0 disease was
done. Outcomes after sublobar resection (n  124) were compared with those after
lobar resection (n  167). Brachytherapy was used in conjunction with 60 (48%)
sublobar resection operations. Analysis based on tumor diameter was performed.
Results: There were 137 cancers smaller than 2 cm and 154 cancers ranging from
2 to 3 cm. Patients undergoing sublobar resection were older (68.4 vs 66.1 years, P
 .018) with poorer pulmonary function (forced expiratory volume in 1 second of
53.1% vs 78.2%, P  .001). Mean follow-up was 34.5 months. Brachytherapy
decreased local recurrence rate significantly among patients undergoing sublobar
resection, from 11 (17.2%) to 2 (3.3%). For tumors smaller than 2 cm, there was no
difference in survival between sublobar resection and lobar resection groups. For the
larger tumors (2-3 cm), median survival was significantly better in the lobar
resection group, at 70 versus 44.7 months (P  .003).
Conclusion: Intraoperative brachytherapy may reduce the local recurrence that is
usually reported with sublobar resection. Our experience supports the further
investigation of the use of sublobar resection with brachytherapy for peripheral
stage IA non–small cell lung cancers smaller than 2 cm.
In 1995, the Lung Cancer Study Group (LCSG) reported the first and onlyrandomized study to compare sublobar resection (SR) and lobar resection(LR) for T1 N0 non–small cell lung cancer (NSCLC).1 The principalfinding in this was a 3-fold increase in local recurrence among patients whounderwent SR. Two years later, a multicenter nonrandomized study com-pared patients who underwent SR (open or video-assisted thoracoscopic
wedge resection) to lobectomy and demonstrated a trend toward increased local
recurrence in the patients who did so.2 As a result of these and other studies, LR has
remained the preferred treatment for NSCLC at most centers.
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optimal treatment for NSCLC. First is an issue of size.
Larger tumors are more likely to display regional or distant
metastases at the time of diagnosis. A Japanese study com-
pared behavior of TI N0 tumors smaller and larger than 2
cm.3 Patients with the larger tumors had an overall poorer
prognosis and an increased incidence of lymphatic and
hematogenous metastases. During the past few years, the
increasing prevalence of computed tomographic scan
screening programs has led to the detection of ever smaller
NSCLCs4; these small tumors may be less aggressive than
larger stage I neoplasms. Therefore, removal of a relatively
large amount of normal lung by LR might be unnecessary
and at times potentially harmful. The use of SR for these
smaller tumors, even for normal-risk patients, is increas-
ingly supported by reports that are emerging, particularly
from Asia.5,6
In light of these reports and concerns regarding the
optimal resection for small NSCLC, we conducted a mul-
ticenter retrospective review to compare outcomes of LR
with SR for patients with T1 N0 cancers. Specific emphasis
in this North American experience has been placed on the
impact of tumor size on outcome. In addition, the more
recent operations have included the use of adjuvant intra-
operative brachytherapy. The effectiveness of this technique
in improving local control was also evaluated.
Patients and Methods
Patients were selected from the research databases of four centers.
Institutional review board approval was obtained, and patient
identifiers were removed from the pooled data in the common
database. Only patients with pathologic T1 N0 NSCLC who un-
derwent SR or LR were included. There were no pneumonecto-
mies in this series.
Patients were selected for SR if they were considered to be at
increased risk with LR. SR procedures included segmental or
wedge resections with pathologically confirmed clear surgical
margins. All patients underwent either lymph node sampling or
lymph node dissection. The approach used (video-assisted thoracic
surgery versus open procedure) was not recorded in the common
data set.
In an effort to decrease local recurrence, adjuvant intraopera-
tive brachytherapy was used in several of the more recent SR
cases.7 In these cases, an iodine 125 implant was fashioned and
placed on the staple line. The 125I seeds were embedded in a Vicryl
polyglactin suture (Ethicon). These sutures were ordered in ad-
TABLE 1. Recurrence rates for tumors smaller than 2 cm
LR (n  80) SR (n  57)* P value
Local recurrence 8 (10.0%) 10 (17.5%) .20
Distal recurrence 15 (18.8%) 8 (14%) .47
*Brachytherapy was used in 22 SRs (38.6%).vance from the manufacturer (Amersham Health, Princeton, NJ).
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(Ethicon) at an appropriate spacing to achieve a prescribed dose of
10,000 to 12,000 cGy to a 0.5-cm depth. The 125I implant was then
secured over the staple line by the thoracic surgeon with an
approximate 2-cm margin. The mesh was secured to the lung with
interrupted 3-0 silk sutures.
Patients were divided into two groups. The first consisted of
those with tumors smaller than 2 cm. The second group included
patients with tumors measuring 2 to 3 cm. In each group, an
analysis of SR versus LR was performed. In particular, the inci-
dences of local and distal recurrence and survival were recorded.
Local recurrence was defined as any recurrence within the same
lobe of the lung, or interlobar and hilar lymph nodes (N1 nodes).
All other metastases were classified as distant recurrence. If a
patient had both local and distal recurrence, they were recorded
separately to get the incidence of each.
After removal of patient identifying information, data from the
study sites was combined and entered into an SPSS file for Win-
dows (version 11.0; SPSS Inc, Chicago, Ill). Statistical analysis
included t test analysis of quantitative data, 2 analysis of dichot-
omous data, and Kaplan-Meier survival analysis with log-rank
analysis to compare groups.
Results
There were 291 patients with T1 N0 disease, including 145
men and 146 women, in this study. The resections per-
formed included 167 LRs and 124 SRs. There were 73
(58.9%) segmentectomies and 51 (41.1%) wedge resections
in the SR group. The SR group patients were older (68.4 
8 years) than the LR group patients (66.1  7.8 years; P 
.018). Additionally, pulmonary function was significantly
worse (P .001) in the SR group (forced expiratory volume
in 1 second [FEV1] 53.1%  21.3%) than in the LR group
(78.2%  22.5%). Patients were stratified into those with
tumors smaller than 2 cm maximum diameter (n 137) and
those with tumors ranging from 2 to 3 cm (n  154). The
histologic types of the cancers were as follows: adenocar-
cinoma (n  127), squamous (n  117) large cell or
adenosquamous (n  27), and bronchiolar (n  20). There
was no preponderance of bronchiolar cancers in either
group, with only 12 (7.2%) in the LR group and 8 (6.5%) in
the SR group having bronchiolar tumors. Since 1997, adju-
vant brachytherapy has been used in conjunction with SR
with increasing frequency in two of the study centers.
Among the 124 SR resections, brachytherapy was per-
formed in 60 cases (48%), with greater use (P .05) for the
2- to 3-cm tumors (n  38, 55.9%) than for those smaller
than 2 cm (n  22, 38.6%). Brachytherapy was used in
similar (P  .46) proportions of the wedge (45%) and
segmental (52%) resections. The mean follow-up for all
patients was 34.5 months.
Tumor Diameter Less Than 2 cm
Recurrence rates for the group with tumors smaller than 2
cm are illustrated in Table 1. As with many other series,
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group. However, this difference was not statistically signif-
icant. Distal recurrence was similar between the groups.
Survival is demonstrated in Figure 1). The mean and median
survivals were 95.8 and 85 months after LR and 82.2 and
55.8 months after SR. These were not significantly different
(P  .97). Cancer caused death in 9 patients (11.3%) in the
LR group and 7 (12.3%) in the SR group. These rates were
not significantly (P  .853) different.
Tumor Diameter From 2 to 3 cm
Local and distant recurrence rates for the 2- to 3-cm tumors
are illustrated in Table 2. The local recurrence rates were
similar in the SR and LR groups. This may have been
related to the greater use of adjuvant brachytherapy for the
larger tumors. Survival is demonstrated in Figure 2). Mean
and median survivals were 70 and 68.7 months after LR and
44.7 and 50.6 months after SR. These were significantly
(P  .003) different. Cancer caused death in 12 patients
(13.8%) in the LR group and 16 (23.9%) in the SR group.
These rates were not significantly different (P  .108).
Impact of Type of SR and Use of Brachytherapy on
Local Recurrence
A further subanalysis was performed of all patients under-
going SR to determine the impacts of the subtype of resec-
tion (wedge or segmentectomy) and the use of adjuvant
brachytherapy on local recurrence. In the 124 patients un-
dergoing SR, local recurrence was seen after 7 (9.6%) of the
segmentectomies and 6 (11.8%) of the wedge resections.
These rates were not significantly (P  .725) different. On
the other hand, the use of brachytherapy significantly (P 
.012) decreased the incidence of local recurrence, from 11
patients (17.2%) to 2 (3.3%).
Discussion
Patients with stage IA NSCLC should ideally be treated by
resection. External beam radiation is traditionally used for
patients who are unable to tolerate any type of pulmonary
resection. However, outcomes of such radiotherapy are in-
ferior to those of operation. In a previous study of 71
node-negative patients who received at least 60 Gy to their
cancers,8 3- and 5-year survivals were 19% and 12%. A
more recent report described results after radiation therapy
in 60 patients with stage I or II cancers.9 Local progression
TABLE 2. Recurrence rates for 2- to 3-cm tumors
LR (n  86) SR (n  68)* P value
Local recurrence 3 (3.5%) 3 (4.4%) .76
Distal recurrence 16 (18.6%) 20 (29.4%) .116
*Brachytherapy was used in 38 SRs (55.9%).occurred in 53% of patients, with a median progression-free
The Journal of Thoracisurvival of 18.5 months and an overall median survival of
20 months. Another study from Duke of 141 patients with
stage I disease demonstrated 2- and 5-year survivals of 39%
and 13%, respectively.10 The overall median survival was
18 months. The median survival, even after SR, was much
longer in our series. A new modality that may offer some
advantages relative to radiation therapy is radiofrequency
ablation. This modality appears to be effective, particularly
for small tumors.11 Currently, however no long-term fol-
low-up data exist. Until long-term outcomes are available,
radiofrequency ablation should be reserved for patients who
are deemed to be at increased risk with pulmonary resection.
A number of factors need to be considered when select-
ing the ideal resection for a patient with a small peripheral
NSCLC. One argument for performing the smallest resec-
tion possible that still allows complete removal of the can-
cer is that by sparing lung parenchyma, lung dysfunction,
morbidity, and mortality are minimized. In an evaluation of
2200 lung resections, mortality was 6.2% after pneumonec-
tomy, 2.9% after lobectomy, and 1.4% after lesser resec-
tions.12 These results suggest that perioperative mortality
would be improved with a lesser resection. A positive
finding that is often overlooked from the randomized LCSG
study of SR and LR is the benefit from SR regarding
preservation of pulmonary function.1 At 6 months the
FEV1, forced vital capacity, and maximal voluntary venti-
lation were all significantly better in the SR group. At 12
months, the FEV1 was still significantly better. Other stud-
ies have also demonstrated better preservation of pulmonary
function with SR.13,14
Higher local recurrence has been the major factor leading
Figure 1. Survival for tumors smaller than 2 cm; SR versus LR
(P  .97).most North American surgeons to abandon SR, except for
c and Cardiovascular Surgery ● Volume 129, Number 2 263
General Thoracic Surgery Fernando et al
G
TScompromised patients. The Rush-Presbyterian group re-
ported a 22% local recurrence rate for patients with stage I
disease after SR, versus 4.9% after LR.15 Similarly, in the
LCSG randomized trial, a 3-fold increase in local recurrence
was seen with LR versus SR.1 Adjuvant external beam
radiation is an option that has been reported to decrease
local recurrence after wedge resection.16 In many ways, this
approach is analogous to a combination of lumpectomy and
external beam radiation, which has become standard ther-
apy for many patients with anatomically favorable breast
cancers.17 In the lung, however, difficulties in precisely
delivering and developing a physics treatment plan for
external beam radiation to the staple line may occur because
of physiologic lung motion and the 3-dimensional irregu-
larity of the target staple line after SR. SR and “postage
stamp” external beam radiation therapy was recently inves-
tigated in a study coordinated by the Cancer and Leukemia
Group.18 In their study, extended radiotherapy fields were
often necessitated by the extent of the postoperative staple
line, and the logistic concerns of daily radiotherapy placed
a hardship on some patients. The advantage of brachyther-
apy is that it provides a means of delivering radiation in a
more uniform manner, with 100% patient compliance and in
the same setting as the lung resection. One study reported
the use of brachytherapy in 33 high-risk patients, primarily
after wedge resection.19 The local recurrence rate was 6.1%,
which was similar to the 6.4% reported after lobectomy in
the LCSG study.1 A study from Pittsburgh compared local
recurrence rates in 98 patients undergoing SR with brachy-
therapy and those in 102 patients undergoing SR alone.20
There was no difference in operative mortality, distal recur-
rence, or survival. However, local recurrence was signifi-
Figure 2. Survival for 2- to 3-cm tumors; SR versus LR (P  .003).cantly reduced, from 18.6% to 2%, among those patients
264 The Journal of Thoracic and Cardiovascular Surgery ● Febrwho received adjuvant brachytherapy. In our study, brachy-
therapy reduced local recurrence significantly to 3.3%
among patients who underwent SR. Brachytherapy was also
used for a higher proportion of the larger, 2- to 3-cm tumors,
which may have accounted for the similarities in local
recurrence rate between the LR and SR group patients with
these larger tumors. The American College of Surgeons
Oncology Group (ACOSOG) is currently developing a ran-
domized study of adjuvant brachytherapy with SR versus
SR alone for patients with T1 N0 NSCLC (Z4032). This
study will include all NSCLC histologic types and will
enroll patients who are considered to be at increased risk
with LR. Cytologic samples will be obtained from the staple
line in all cases as an additional evaluation of resection
margin. It is to be hoped that the ACOSOG study will
confirm the beneficial results of this and other nonrandom-
ized reports regarding the use of adjunctive intraoperative
brachytherapy with SR for NSCLC.
Tumor size is an important factor when planning inter-
vention for NSCLC. One study from Japan reported on
segmentectomy in 74 patients with T1 N0 NSCLC.21 Over-
all 5-year survival was 82%, but it was greater at 92% for
tumors 2 cm or smaller than for larger tumors (2.1-3 cm),
for which survival was 63% at 5 years. Additionally locore-
gional recurrence was seen in only 1.9% of the patients with
smaller tumors, versus 33.3% of those with the larger tu-
mors. Another Japanese study compared the results of ex-
tended segmentectomy with those of lobectomy for patients
with T1 N0 tumors 2 cm or smaller.22 The 5-year survivals
were 87.1% in the segmentectomy group and 87.7% in the
lobectomy group.
We accept the current consensus that lobectomy is the
current standard of care for the treatment of stage IA
NSCLC. However, our findings and those of others21,22 are
compelling in suggesting that SR with brachytherapy may
provide adequate local therapy, at least for tumors smaller
than 2 cm, even for low-risk patients. There remain some
caveats. If smaller tumors are treated with SR, there remains
a risk that lymph node metastases may be missed and that
adequate staging of hilar and mediastinal lymph nodes
might not accompany the resection. This was demonstrated
in a series of 100 patients with NSCLC 1 cm or smaller, in
which there was a 5% incidence of unsuspected N1 dis-
ease.23 For this reason, we recommend lymph node dissec-
tion or sampling whenever SR is performed.
We believe that there are differences in the type of SR
and favor anatomic segmentectomy when possible. We
were surprised to see similar recurrence rates with segmen-
tectomy and wedge resection. Factors that may have ac-
counted for this are the small size of many of the tumors, the
routine use of lymph node dissection or sampling, exclusion
of patients with unsuspected nodal disease, and, finally,
brachytherapy, which was used in 48% of the SR resections.
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local recurrence rates when comparing SR with LR, surviv-
als are usually similar. In this study, no differences were
seen in survival with the smaller (2 cm) tumors, despite
physiologic differences favoring the LR group. With the 2-
to 3-cm tumors, however, there was a marked difference in
survival, favoring the lobectomy group. Our data (although
not statistically significant) suggest that this difference may
have been attributable to cancer-related death.
In conclusion, adjuvant brachytherapy appears to be a
promising modality that may reduce local recurrence rate
after SR. Additionally there are differences in outcome
between smaller and larger T1 N0 cancers. Until further
randomized studies are available, lobectomy should be used
whenever possible. If the results of the upcoming ACOSOG
study confirm the results from the preliminary studies on the
use of brachytherapy, we suggest that a follow-up trial
compare SR with brachytherapy versus lobectomy for all
patients with small (2 cm) NSCLC.
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Discussion
Dr Joseph P. Shrager (Philadelphia, Pa). It’s a pleasure to be
able to discuss one of your articles. I congratulate you and your
colleagues on this potentially very important work and on the
foresight of starting to use brachytherapy all the way back before
1997, as I gather.
Although the question of the equivalence of SR and lobec-
tomy had seemingly been put to rest by the LCSG trial, there
has been increasing interest in this subject as we have begun to
detect more small tumors. The interest in these procedures has,
appropriately I think, been heightened by the additional evi-
dence that small tumors that are predominantly bronchoalveolar
cell cancer (BAC) have a very low likelihood of nodal metas-
tasis and can be reliably identified by preoperative computed
tomographic scan criteria.
Several retrospective studies, including the one you nicely
presented here today, have been interpreted as suggesting that
either all tumors below a certain size, or at least small BAC-
predominant tumors, can be effectively managed with SR. How-
ever, I believe it’s appropriate to sound a note of caution on this
issue. Although I applaud the carefulness with which your con-
clusions are offered, it’s critical to reiterate that any number of
retrospective studies cannot compete with the scientific validity of
a single large, prospective, randomized trial, such as the LCSG
trial. Further, the initial rationale for SR—that many patients
cannot tolerate a lobectomy—has always struck me as somewhat
weak, and I think it only gets weaker with time as we increasingly
c and Cardiovascular Surgery ● Volume 129, Number 2 265
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reduction benefit” from their lobectomy.
Finally, other than BAC tumors, there is clear evidence from
the Mayo and from Japan that as many as 30% of patients with
tumors smaller than 2 cm have N1 or N2 disease.
Looking specifically at the data you presented here, I believe
that they also do not support a conclusion that SR alone without
brachytherapy is broadly reasonable even for lesions smaller than
2 cm. In the absence of brachytherapy, your reported local recur-
rence rate in this group was about 26%. With more patients and a
longer follow-up, one would have to believe that this would
translate into a survival difference. On the other hand, I believe the
data that you present here and that others have presented are very
impressive with regard to the effectiveness of brachytherapy in this
setting. I think the data on this issue strongly suggest that for the
rare patient who is truly not a candidate for a lobectomy, adding
brachytherapy to SR may well be appropriate. And if we ever do
cross that threshold of sufficient evidence proving that SR is
equivalent to lobectomy for some subset of noncompromised
patients, then I believe it’s likely that we will be doing that in
conjunction with brachytherapy, on the basis of what you show
here and what others have shown.
I agree with you that this is an area ripe for a planned,
prospective, clinical trial, and ultimately it’s quite possible that this
approach will be proved to be appropriate for some subset of
tumors. Until definitive data become available, however, I feel
pretty strongly that it’s the responsibility of this specialty, of the
people in this room, to strongly advocate lobectomy unless a
patient is considered to be at extraordinary risk with this operation.
I think the temptation to do an easier operation, such as a wedge
resection, is so great that if the thought leaders in this area do not
continue to advocate lobectomy unless there are very strong data to
the contrary, we will have potentially inappropriate wedge resec-
tions being done as common practice.
I have the following specific questions. First, you did not tell us
here today and I don’t see in the article exactly how the margins
were checked intraoperatively. Everyone in this room knows the
pitfalls of trying to get frozen sections on stapled margins. I have
been impressed with the work from a couple of Japanese groups
demonstrating that two methods of checking cytology on stapled
margins are highly accurate in predicting local recurrence or lack
of local recurrence.
Dr Patterson. Would you answer the question about the frozen
section?
Dr Fernando. In terms of the intraoperative management, this
is a difficult thing to answer in this retrospective multicenter study.
I think that the future ACOSOG study will better address this,
because we plan to look at the margins and we also plan to do a
smear of the staple line as part of that protocol. I think this is an
important issue, and this may be where brachytherapy has the most
importance in that you do get a better margin.
When you do wedge resection at the moment, you are usually
doing this for a compromised patient, and I think you are going to
find patients with margins that are close. The addition of brachy-
therapy may improve this, which may account for the local recur-
rence rates we are seeing. Also, in the Japanese data, as you know,
they do very extensive lymph node dissections and maybe in some
cases extended segmentectomies, and they still seem to have these
266 The Journal of Thoracic and Cardiovascular Surgery ● Febrlow local recurrence rates which we don’t see over here in the
United States with limited resection.
Dr Shrager. You didn’t tell us the histologic types of your
tumors. I would think that BACs are likely to be the subset of
tumors for which we would ultimately be doing this sort of
procedure. So what were the percentage of tumors that were pure
or predominantly BAC?
Dr Fernando. I do not have that data at this time. However, it
was a small percentage.
Dr Shrager. If the concept of a wedge resection for small
tumors begins to gain acceptance, I think the natural course of
events will be that a lot of people will be doing that by video-
assisted thoracoscopic surgery. My personal belief is that this
would lead to more incomplete resections and inferior lymph node
dissections. Do you know what percentage of these were video-
assisted thoracoscopic surgery versus open wedge resections?
Dr Fernando. It was a very small percentage, I think about 5%.
I do not know the answer exactly, but it was a small percentage.
Dr Thomas A. D’Amico (Durham, NC). I have two questions.
How do you explain the apparent paradox of the higher local
recurrence rate for smaller tumors than for larger tumors?
Dr Fernando. I wondered about that, and I believe that this
may have been due to the greater use of brachytherapy for these
larger tumors. On the other hand, you may expect closer margins
with the larger tumors, so I cannot explain these results from our
current data.
Dr D’Amico. Second, maybe you could share your thinking
regarding for which patients you would do SR, because I think that
probably matters. For example, you would never do a posterior
segmentectomy on someone with advanced emphysema, leaving
the worst anterior and apical segments in. You would do a lobec-
tomy. For someone with restrictive lung disease and a superior
segment tumor, you probably would perform segmentectomy.
Does that go into your thinking when you plan SR versus LR?
Dr Fernando. I think, first of all, these have to be peripheral, not
central tumors. At the current time, we only use SR for those patients
whom we consider to be compromised and believe would benefit
from that lesser resection. I think if you have a tumor nodule within
the upper lobe in an area of the worst emphysema, it makes more
sense to do a lobectomy with the current data. As we develop the
long-term data from the ACOSOG study, I think we really have to
look at what we should be doing for these smaller tumors.
Dr William H. Warren (Chicago, Ill). Your methods lead me
to conclude that you think your local recurrences are only in your
staple line. As someone who has gone on record critical of seg-
mentectomy, I’m sure I’ve seen drop metastases and recurrence
from nodes that are deep in the lobe and not resected with the
segment. Can you please define for us what you mean by local
recurrence?
Dr Fernando. Local recurrence is within the same tumor lobe
and also includes hilar lymph nodes as well.
Dr Warren. That would not be treated with the brachytherapy?
Dr Fernando. The lymph nodes would not be treated by the
brachytherapy.
Dr Joseph Miller (Atlanta, Ga). I have two quick points. One
regards your classification of poor pulmonary function. The FEV1
was listed as 53% in your abstract. I would submit that this is not
poor pulmonary function. You could probably easily get away with
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caution. I do not think we need to move forward into this. In the
1980s, we published a group with pulmonary function of 35% to
40% comparing 20 versus 20 treated with cone-down radiation at
that point to 4500 rads. The recurrence rate went from 20%
without radiation to 7.5%, which is close to yours. But I do not
think we want to move toward doing this operation with brachy-
therapy if, when the patients have an FEV1 of 51%, a lobectomy
can be done, which has remained the criterion standard.
Dr Fernando. I disagree a little bit, Dr Miller. We do quote
your article in our manuscript. External beam radiation was also
looked at by the Cancer and Leukemia Group in a study with
postage stamp radiation after sublobar resection. The problem with
external beam radiation is that it is difficult to precisely identify the
staple line and there is the additional issue of lung motion. The
advantage of brachytherapy is that you are placing this right over
the staple line, delivering the radiation in a more uniform fashion,The Journal of ThoraciI agree that you could perform a lobectomy on many of these
patients, but you have to also look at the quality of life. If you
look at the Lung Cancer Study Group data, at 6 months in three
pulmonary function parameters, pulmonary function was actu-
ally better in the segmentectomy group. At 12 months the FEV1
was still better in the segmentectomy group. I think if you
preserve or improve quality of life, you achieve the same
survival and also decrease the local recurrence rate to the same
as lobectomy, then I believe you are doing the patients a
service.
Dr Thomas M. Egan (Chapel Hill, NC). Because any amount
of radiation damages normal lung, do you have postoperative
pulmonary function test results and diffusing capacity for carbon
monoxide values for any of these patients?
Dr Fernando. We do not in this particular study. Again, that is
going to be looked at in the ACOSOG study; the plan is to look at
postoperative pulmonary function and also to look at dyspneaand minimizing radiation injury to the remaining lung. scores in these patients as well.c and Cardiovascular Surgery ● Volume 129, Number 2 267
